Editorials

A year ago, we adopted an ethics framework to help with the assessment of and to increase transparency and accountability for research practices in studies involving partnerships between researchers in high- and low-income settings. We now reflect on our progress, what we learned and the way forward to champion ethical, inclusive and equitable partnerships in the content we publish.

Incretin-based drugs have demonstrated unprecedented efficacy in weight-loss trials, but ensuring that healthy body weight can be maintained is fundamental to sustainable good health.

The approval of two vaccines and a monoclonal antibody that target respiratory syncytial virus could shift the tide on the prevention and treatment of infection with this virus.

Twenty years after completion of the Human Genome Project, genetics is rapidly being integrated into everyday clinical practice. But in this era of genomic revolution, genetically trained teams of healthcare workers are needed to optimize delivery of patient care.

In this issue, we ask what it takes to build a healthier future for populations — a necessary condition to deliver on the commitments of the United Nations Sustainable Development Goals.

Promising results from recent trials of personalized vaccines against cancer highlight the potential and challenges of precision vaccines.

From menarche to menopause, menstrual health is intrinsically linked to general health and must find regular attention in clinical practice.

Dietary interventions have the potential to treat a wide variety of chronic conditions and diseases, but generating strong evidence and a framework for their integration into health systems will be critical for their success.

ChatGPT and other large language models may be able to enhance healthcare delivery and patients’ quality of life. But they will need to be tailored to specific clinical needs first.

The international community needs to prioritize research on interventions and preventative measures for dementia that are likely to produce the greatest global impact.

We are launching a series on evidence in medicine, to discuss new approaches to assessing the safety and efficacy of cutting-edge health technologies and treatments.

Checkpoint-blockade immunotherapy has transformed cancer therapeutics but still benefits only a subset of patients. The development of more-robust biomarkers of response could change that.

New initiatives aimed at reducing the burden of diabetes are laudable, but they will have to account for the disease’s complexity and heterogeneity to be truly effective and equitable at a global scale.

In this issue, Nature Medicine presents the Burden of Proof studies led by the Institute for Health Metrics and Evaluation, which quantitatively evaluate the strength of evidence of risk–outcome relationships to better inform effective clinical and policy recommendations.

Advances in the applications of artificial intelligence and other technologies in health and medicine require rethinking of what patient safety means.

Governments and funders must prioritize research on emerging and re-emerging infectious diseases such as monkeypox to prevent another pandemic.

The US Supreme Court’s majority decision to overturn the constitutional protection of the right to seek an abortion threatens the health of all Americans.

We are raising the standards on reporting on sex and gender in research. Starting this June, authors will be prompted to provide details on how sex and gender were considered in study design.

With the increase in genomic data available and the advent of new technology for mining it, balancing the needs for data sharing and data protection becomes more challenging. Different disciplines must come together to find new solutions.

New treatments and technologies offer exciting prospects for cancer research and care, but their global impact rests on widespread implementation and accessibility.